🇦🇺Australia

HREC and SSA Approval Delays

2 verified sources

Definition

Biotech clinical trials require parallel HREC ethics approval and SSA at each site, with institutional authorisation dependent on manual submissions to RGOs.

Key Findings

  • Financial Impact: 20-40 hours per trial site (at AUD 200/hr = AUD 4,000 - 8,000 opportunity cost)
  • Frequency: Per research project or site
  • Root Cause: Manual ethics reviews and SSA processes across jurisdictions

Why This Matters

The Pitch: Biotechnology research in Australia 🇦🇺 loses 20-40 hours per trial on HREC/SSA processes. Automation of ethics submissions eliminates this drag.

Affected Stakeholders

Clinical Trial Managers, Ethics Coordinators, Site Investigators

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

TGA CTN/CTA Notification Costs

30-60 hours per trial (at AUD 250/hr specialist rate = AUD 7,500 - 15,000)

Biosafety Non-Compliance Fines

AUD 10,000 - 500,000 per breach (typical civil penalty range for regulatory contraventions)

Embryo Research Licensing Overhead

15-30 hours per licence application (AUD 3,000 - 6,000 at AUD 200/hr)

TGA Non-Compliance Penalties

AUD 50,000 - 500,000 per violation (civil penalties up to 5,000 penalty units at AUD 313/unit); 20-40% trial budget overrun from delays.

Delayed RDTI Tax Incentive Claims

AUD 100,000 - 1M forgone refund per delayed claim; 6-12 month ATO processing drag.

Datenmanipulation und Verstoß gegen Aufbewahrungspflichten in Forschungsvorhaben

Quantified (logic-based): For a typical biotechnology clinical or translational research project with a total budget of AUD 5–20 million, suspension or major protocol non‑compliance can reasonably jeopardise 2–5% of funding and add 1–2% in remedial compliance costs (≈ AUD 100,000–700,000 per affected project) through lost milestone payments, remedial monitoring and legal/consulting costs.

Request Deep Analysis

🇦🇺 Be first to access this market's intelligence